Hims Shares Head for Record Week After Novo Nordisk Deal

Shares of U.S.-based telehealth company Hims & Hers Health rallied sharply after the company announced a new collaboration with Danish pharmaceutical giant Novo Nordisk. The stock surged more than 30% at the start of the week, putting it on track for the strongest weekly performance in its history.

Under the agreement, Hims & Hers will offer Novo Nordisk’s widely used weight‑loss and diabetes medications, including Wegovy and Ozempic, through its digital health platform. Both injectable and oral versions of the treatments are expected to become available to patients through the service.

The partnership also resolves a recent legal dispute between the two companies. Novo Nordisk had previously filed a patent infringement lawsuit after Hims & Hers announced plans to introduce a cheaper compounded version of semaglutide, the active ingredient used in Wegovy. Hims later abandoned those plans, paving the way for the new agreement.

As part of the deal, Hims & Hers will stop advertising compounded GLP‑1 weight‑loss medications on its platform. Analysts say the removal of legal uncertainty and access to blockbuster obesity drugs could strengthen the company’s position in the rapidly expanding digital healthcare and weight‑loss treatment market.